AGING POPULATION
COSTS AND SPENDING
FOR-PROFIT
MORE NOT ALWAYS BETTER
HEALTH MORE THAN HEALTHCARE
PATIENT PAYS
SUSTAINABILITY
WAITING FOR CARE
MENTAL HEALTH
OBESITY
PHARMACEUTICAL POLICY
  • Home
  • About
    • Contact
  • Experts
    • By Topic
    • By Geographic Region
  • Backgrounders
  • Commentaries
    • English
    • French
  • Our Videos
    • Our Videos
    • Featured Videos
  • Resources

Evidence Network
rsz_gagnon_marcandre
Skip to content
  • Home
  • About
    • Contact
  • Experts
    • By Topic
    • By Geographic Region
  • Backgrounders
  • Commentaries
    • English
    • French
  • Our Videos
    • Our Videos
    • Featured Videos
  • Resources
     
Share
Print Friendly and PDF

Marc André Gagnon

Marc André Gagnon, PhD
Carleton University
Pharmaceutical Policies

613-520-2600 ext. 1690 | ma_gagnon@carleton.ca
(Available for interviews in French/English)

Marc-Andre Gagnon is an expert in political economy and health policy. He is an Assistant Professor at the School of Public Policy and Administration at Carleton University. He is also a Research Fellow with the Pharmaceutical Policy Research Collaboration and with the Edmond J. Safra Centre for Ethics at Harvard University for a Lab Project on Institutional Corruption. His current research focuses on Drug pricing, Pharmacare, Innovation Policy, Pharmaceutical Promotion and the corruption of medical research. Marc-Andre holds a PhD in Political Science from York University and a Masters of Advanced Study in Economics from Paris-1 Sorbonne and Ecole Normale Superieure de Fontenay/St-Cloud.

Download a hi-res photo of Marc André Gagnon

Commentaries by Marc André Gagnon:

Who’s afraid of universal pharmacare?
Beware the ghosts of medical research // Gare aux fantômes qui hantent la recherche médicale
How Canada artificially inflates the cost of prescription drugs to the tune of $2-billion // Médicaments: Un gaspillage annuel de deux milliards
Our drug plan; costly, inefficient and inequitable

Provinces must stand together on drug purchases
Quelle stratégie québécoise pour l’accès au médicament?
Patent protection for brand name drugs should come at a price // Il devrait y avoir un prix à payer pour la protection par brevet des médicaments d’origine

Comments are closed.


Find an Expert

We have experts (listed by topic and by geographic region) who are ready and able to answer media questions and connect you with the evidence on issues in Canadian health policy.


We are here to help you quickly make sense of complex health policy issues. We can help you understand what evidence is out there and how to put new evidence into context.

Review the evidence, browse how these topics have been discussed in the news or go directly to our list of health policy experts organized by topic or by region.


  • Join Our Mailing List!


  • Thomson: Mishandling of changes to PDD and home care haunting premier and cabinet

    Graham Thomson.
    Edmonton Journal

    Exercise and mental health

    Mike Sprung.
    Black Hills Pioneer

    Target obesity with health care reform: Column

    Tommy Thompson and Kenneth Thorpe.
    USA Today


    Our Topics

    AGING POPULATION
    COSTS AND SPENDING
    HEALTH MORE THAN HEALTHCARE
    INTERNATIONAL HEALTH SYSTEMS
    FOR-PROFIT
    MENTAL HEALTH
    MORE NOT ALWAYS BETTER
    OBESITY
    PATIENT PAYS
    PHARMACEUTICAL POLICY
    SUSTAINABILITY
    WAITING FOR CARE
    OBESITY
    MENTAL HEALTH
    PHARMACEUTICAL POLICY


    Evidence Network
    Proudly powered by WordPress.

    • PRIVACY STATEMENT
    • TERMS OF USE
    • CONFLICT OF INTEREST POLICY
    • CONTACT
    Site development provided in part by:
         Copyright EvidenceNetwork.ca